In the past decade, Clostridium difficile infections (CDIs) have become a major public health challenge. Their epidemiology has radically changed with a significant rise in the number of cases and an increase in severe episodes. Recurrence and failure of conventional treatments are very common. Furthermore, a spread of CDI has emerged in general population without the usual risk factors (unexposed to antibiotic treatment, young people, etc.). The conventional treatments (metronidazole and vancomycin) are still effective and are the first-line antibiotics with new recommendations. New therapeutic strategies are now available. Recent studies show a better efficacy of vancomycin compared with metronidazole for severe episodes. Fidaxomicin is a novel antibiotic drug with an efficacy similar to vancomycin and a lower risk of recurrence. Finally, for relapsing forms, fecal microbiota transplantation (FMT) seems to be the best option. We determined risk factors for CDI among patients treated at the infectious diseases ward of our hospital in Pécs. The study included 886 patients with CDI from 2009 to 2014. The average number of recurrent episodes was 2.16 and the proportion of severe cases was 66%. Among our patients, 726 (82%) had taken antibiotics and 769 (86.8%) had been hospitalized in the prior 3 months before developing CDI. We have found that prior statin use could be a significant risk factor of CDI (OR: 1.7765, 95% CI: 1.3966–2.2597, p < 0.0001). Finally, we present the comparative efficacy of different types of treatment (metronidazole, vancomycin, fidaxomicin, and FMT).
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Hall, I. C., O’ Toole, E.: Intestinal flora in newborn infants: With a description of a new pathogenic anaerobe, Bacillus difficile. Am J Dis Child 49, 390 (1935).
-
2.
Larson, H. E., Price, A. B., Honour, P., Borriello, S. P.: Clostridium difficile and the etiology of pseudo membranous colitis. Lancet 1, 1063–1066 (1978).
-
3.
McDonald, L., Owings, M., Jernigan, D.: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12, 409–415 (2006).
-
4.
Lucado, J., Gould, C., Elixhauser, A.: Clostridium difficile infections (CDI) in hospital stays. Statistical brief # 124. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. Available at http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf (accessed on March 27, 2012).
-
5.
Warny, M., Pepin, J., Fang, A., Kilgore, G. E., Thompson, A., Brazier, J., Frost, E., McDonald, M. C.: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079–1084 (2005).
-
6.
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Jr., Kazakova, S. V., Sambol, S. P., Johnson, S., Gerding, D. N.: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353, 2433–2441 (2005).
-
7.
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, M. D., Nguyen, T., Frenette, C., Kelly, M., Vibien, A., Brassard, P., Fenn, S., Dewar, K., Hudson, T. J., Horn, R., René, P., Monczak, Y., Dascal, A.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353, 2442–2449 (2005).
-
8.
Goudarzi, M., Seyedjavati, S. S., Goudarzi, H., Goudarzi, H., Aghdam, E. M., Nazeri, S.: Clostridium difficile infection: Epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica 2014, 916826 (2014).
-
9.
Barbut, F., Jones, G., Eckert, C.: Epidemiology and control of Clostridium difficile infections in healthcare settings: An update. Curr Opin Infect Dis 24, 370–376 (2011).
-
10.
Kuijper, E. J., Barbut, F., Brazier, J. S., Kleinkauf, N., Eckmanns, T., Lambert, M. L., Drudy, D., Fitzpatrick, F., Wiuff, C., Brown, D. J., Coia, J. E., Pituch, H., Reichert, P., Even, J., Mossong, J., Widmer, A. F., Olsen, K. E., Allerberger, F., Notermans, D. W., Delmée, M., Coignard, B., Wilcox, M., Patel, B., Frei, R., Nagy, E., Bouza, E., Marin, M., Akerlund, T., Virolainen-Julkunen, A., Lyytikäinen, O., Kotila, S., Ingebretsen, A., Smyth, B., Rooney, P., Poxton, I. R., Monnet, D. L.: Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13, 18942 (2008).
-
11.
Bauer, M. P., Goorhuis, A., Koster, T., Numan-Ruberg, S. C., Hagen, E. C., Debast, S. B., Kuijper, E. J., van Dissel, J. T.: Community-onset Clostridium difficile diarrhoea not associated with antibiotic usage – Two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea. Neth J Med 66, 207–211 (2008).
-
12.
Bauer, M. P., Notermans, D. W., van Benthem, B. H. B., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., Kuijper, E. J.: Clostridium difficile infection in Europe: A hospital-based survey. Lancet 377, 63–73 (2011).
-
13.
Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., McFarland, L. V., Mellow, M., Zuckerbraun, B. S.: Guidelines for diagnoses, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108, 478–498 (2013).
-
14.
Vesteinsdottir, I., Gudlaugsdottir, S., Einarsdottir, R., Kalaitzakis, E., Sigurdardottir, O., Bjornsson, E. S.: Risk factors for Clostridium difficile toxin-positive diarrhea: A population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 31, 2601–2610 (2012).
-
15.
Bavishi, C., DuPont, H. L.: Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 34, 1269–1281 (2011).
-
16.
Deshpande, A., Pant, C., Pasupuleti, V., Rolston, D. D. K., Jain, A., Desphande, N., Thota, P., Sferra, T. J., Hernandez, A. V.: Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 10, 225–233 (2012).
-
17.
Janarthanan, S., Ditah, I., Adler, D. G., Ehrinpreis, M. N.: Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am J Gastroenterol 107, 1001–1010 (2012).
-
18.
Kwok, C. S., Arthur, A. K., Anibueze, C. I., Singh, S., Cavallazzi, R., Loke, Y. K.: Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 107, 1011–1019 (2012).
-
19.
Motzkus-Feagans, C. A., Pakyz, A., Polk, R., Gambassi, G., Lapane, K. L.: Statin use and the risk of Clostridium difficile in academic medical centers. Gut 11, 1538–1542 (2012).
-
20.
Naggie, S., Miller, B. A., Zuzak, K. B., Pence, B. W., Mayo, A. J., Nicholson, B. P., Kutty, P. K., McDonald, L. C., Woods, C. W.: A case-control study of community-associated Clostridium difficile infection: No role for proton pump inhibitors. Am J Med 124, 276.e1–276.e7 (2011).
-
21.
Park, S. W., Choi, A. R., Lee, H. J., Chung, H., Park, J. C., Shin, S. K., Lee, S. K., Lee, Y. C., Kim, J. E., Lee, H.: The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 38, 613–627 (2013).
-
22.
Saliba, W., Barnett-Griness, O., Elias, M., Rennert, G.: Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect 20, 1061–1066 (2014).
-
23.
Elashery, A., Sohi, S., Qi, Y., Chandra, S.: Statin use and hospital-onset Clostridium difficile infection; A case control study. Infect Drug Resist 11, 405–416 (2018).
-
24.
McGuire, T., Dobesh, P., Klepser, D., Rupp, M., Olsen, K.: Clinically important interaction between statin drugs and Clostridium difficile toxin? Med Hypotheses 73, 1045–1047 (2009).
-
25.
Kurti, Zs., Lovasz, B. D., Mandel, M. D., Csima, Z., Golovics, P. A., Csako, B. D., Mohas, A., Gönczi, L., Gecse, K. B., Kiss, L. S., Szathmari, M., Lakatos, P. L.: Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe. World J Gastroenterol 21, 6728–6735 (2015).
-
26.
Terhes, G., Urban, E., Soki, J., Szikra, L., Konkoly-Thege, M., Vollain, M., Nagy, E.: Assessment of changes in the epidemiology of Clostridium difficile isolated from diarrheal patients in Hungary. Anaerobe 15, 237–240 (2009).
-
27.
Nassir Al, W. N., Sethi, A. K., Nerandzic, M. M., Bobulsky, G. S., Jump, R. L. P., Donskey, C. J.: Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 47, 56–62 (2008).
-
28.
Musher, D. M., Aslam, S., Logan, N., Naracheru, S., Bhaila, I., Borchert, F., Hamill, R. J.: Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40, 1586–1590 (2005).
-
29.
Debast, S. B., Bauer, M. P., Kuijper, E. J.: Euopean Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20, 1–26 (2014).
-
30.
Cornely, O. A., Nathwani, D., Ivanescu, C., Odufowora-Sita, O., Retsa, P., Odeyemi, I. A. O.: Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: A meta-analysis and indirect treatment comparison. J Antimicrob Chemother 69, 2892–2900 (2014).
-
31.
Varier, R. U., Biltaji, E., Smith, K. J., Roberts, M. S., Jensen, M. K., LaFleur, J., Nelson, R. E.: Cost-effectiveness analysis of treatment strategies of Clostridium difficile infection. Clin Microbiol Infect 20, 1343–1351 (2014).
-
32.
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., Wilcox, M. H.: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31, 431–455 (2010).
-
33.
Nagy, G. Gy., Várvölgyi, Cs., Balogh, Z., Orosi, P., Parragh, Gy.: Recommendation for the methodology of fecal transplantation used for treatment of Clostridium difficile associated diarrhea. Orv Hetil 154, 10–19 (2013).
-
34.
Vigvari, S., Nemes, Z., Vincze, A, Solt, J., Sipos, D., Feiszt, Z., Kappéter, Á., Kovács, B., Péterfi, Z.: Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection. Orv Hetil 155, 1758–1762 (2014).
-
35.
Mitchell, B. G., Gardner, A.: Mortality and Clostridium difficile infection: A review. Antimicrob Resist Infect Control 1, 20 (2012).
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Oct 2020 | 29 | 0 | 0 |
| Nov 2020 | 6 | 1 | 0 |
| Dec 2020 | 7 | 0 | 0 |
| Jan 2021 | 15 | 0 | 0 |
| Feb 2021 | 15 | 1 | 1 |
| Mar 2021 | 18 | 1 | 1 |
| Apr 2021 | 4 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory